Tumour necrosis factor and other cytokines in murine lupus

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Theofilopoulos, Argyrios N ^a,b   Lawson, Brian R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Immunology Department/IMM3   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING AGENT; CYTOKINE; TUMOR NECROSIS FACTOR;

CYTOKINE PRODUCTION; KNOCKOUT MOUSE; LUPUS ERYTHEMATOSUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

EID: 0032725836     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2008.i49     Document Type: Review

References (98)

1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
2. Rincon M, Flavell RA. T-cell subsets: transcriptional control in the Th1/Th2 decision. Curr Biol 1997;7:R729-32.
3. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-96.
4. Chow CW, Rincon M, Davis RJ. Requirement for transcription factor NFAT in interleukin-2 expression. Mol Cell Biol 1999;19:2300-7.
5. Rincon M, Enslen H, Raingeaud J, et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 1998;17:2817-29.
6. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med 1998;188:1859-66.
7. Altman A, Theofilopoulos AN, Weiner R, Katz DH, Dixon FJ. Analysis of T cell function in autoimmune murine strains. Defects in production of, and responsiveness to, interleukin 2. J Exp Med 1981;154:791-808.
8. Dauphinee MS, Kipper SB, Wofsy D, Talal, N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981;127:2483-7.
9. - T cell subset completely lacks functional IL-2 receptors. Eur J Immunol 1993;23:1378-80.
10. -CD8 T lymphocytes results in constitutive expression of a novel nuclear factor of activated T cells-binding factor. J Immunol 1995;154: 6372-81.
11. Liang HE, Hsueh YP, Wu CC, Han SH, Lai MZ. Atypical signaling defects prevent IL-2 gene expression in lpr/lpr CD4-CD8-cells. J Biomed Sci 1998;5:297-304.
12. tyn in their activation and expansion. J Immunol 1997;159:2265-73.
13. + cells of older lupus mice. Eur J Immunol 1997;27:1901-10.
14. fvn expression. Eur J Immunol 1994;24:558-65.
15. Huang FP, Stott DI. Restoration of an early, progressive defect in responsiveness to T-cell activation in lupus mice by exogenous IL-2. Autoimmunity 1993;15:19-29.
16. Radvanyi LG, Raju K, Spaner D, Mills GB, Miller RG. Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. Cellular Immunol 1998;183:1-12.
17. Gutierrez-Ramos JC, Andreu JL, Revilla Y, Vinuela E, Martinez C. Recovery from autoimmunity of MRL/lpr after infection with an interleukin-2/vaccinia recombinant virus. Nature 1990;346:271-4.
18. Huggins ML, Huang F-P, Xu D, Lindop G, Stott DI. Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-β1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus 1999;8:29-38.
19. Raz E, Dudler J, Lotz M, et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995;4:286-92.
20. Owen KL, Shibata T, Izui S, Walker SE. Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse. J Biol Response Mod 1989;8:366-74.
21. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom TB. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 1988;140:59-68.
22. Rocchieri MH, Knittweis L, Seaton DA. Cytokine production by NZB, C58 and NZBxC58 recombinant inbred mice. Cell Immunol 1984,88:453-63.
23. Davidson WF, Roths JB, Holmes, KL, Rudikoff E, Morse HE III. Dissociation of severe lupus-like disease from polyclonal B cell activation and IL2 deficiency in C3H-lpr/lpr mice. J Immunol 1984;133:1048-56.
24. Abe C, Koyama A, Nishimura T. Interleukin-2 induction, response and therapy on murine lupus lesions in the MRL/1 strain. Prog Clin Biol Res 1987;229:147-56.
25. + T cells. Eur J Immunol 1995;25:3053-9.
26. Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interieukin-2 receptor β. Science 1995;268:1472-6.
27. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt F. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995;3:521-30.
28. Davidson WF, Calkins C, Hugins A, Giese T, Holmes KL. Cytokine secretion by C3H-lpr and -gld T cells. Hypersecretion of IFN-gamma and tumor necrosis factor-alpha by stimulated CD4+T cells. J Immunol 1991;146:4138-48.
29. Prud'homme GJ, Kono DH, Theofilopoulos AN. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1β, interleukin-10, and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol 1995;32:495-503.
30. Shirai A, Conover J, Klinman DM. Increased activation and altered ratio of interferon-gamma: Interleukin-4-secreting cells in MRL-lpr/lpr mice. Autoimmunity 1995;21:107-16.
31. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZBxNZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987;166:798-803.
32. Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G. Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995;25:6-12.
33. Takahashi S, Fossati L, Iwamoto M, et al. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest 1996;97;1597-604.
34. Peng SL, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997;99:1936-46.
35. Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998;101:364-71.
36. Haas C, Ryffel B, LeHir M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/ lpr mice. J Immunol 1997;158:5484-91.
37. lpr mice. J Immunol 1998;161:494-503.
38. Haas C, Ryffel B, LeHir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZBxNZW)F1 mice. J Immunol 1998; 160:3713-18.
39. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-4.
40. Alleva DG, Kaser SB, Beller, D.I. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. J Immunol 1998;161:6878-84.
41. lpr/lpr mice. J Exp Med 1996;183:1447-59.
42. Fan X, Oertli B, Wuthrich RP. Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Fas (lpr) mice with renal injury. Kidney Int 1997;51:79-86.
43. Weinberg JB, Granger DL, Pisetsky DS, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994;179:651-60.
44. 1 mice. J Immunol 1997;158:1466-72.
45. McMurray RW, Hoffman RW, Nelson W, Walker SE. Cytokine mRNA expression in the B/W mouse model of systemic lupus erythematosus - analyses of strain, gender, and age effects. Clin Immunol Immunopathol 1997;84; 260-8.
46. Chen SY, Takeoka Y, Pike-Nubile L, Ansari AA, Boyd R, Gershwin ME. Autoantibody production and cytokine profiles of MHC class 1 (β2-microglobulin) gene-deleted New Zealand Black (NZB) mice. Clin Immunol Immunopathol 1997;84:318-27.
47. Ohteki T, Okamoto S, Nakamura M, Nemoto E, Kumagai K. Elevated production of interleukin 6 by hepatic MNC correlates with ICAM-1 expression on the hepatic sinusoidal endothelial cells in autoimmune MRL/lpr mice. Immunol Lett 1993;36:145-52.
48. 1 spleen cells by eliminating the main source of IL-6. Clin Exp Immunol 1993;91:220-5.
49. 1 mice. Am J Pathol 1994;144:927-7.
50. 1 mice. J Clin Invest 1994;94:585-91.
51. Kiberd BA. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 1993;4:58-61.
52. Santiago M-L, Fossati L, Jacquet C, Muller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 1997;185: 65-70.
53. Schorlemmer HU, Dickneite G, Kanzy EJ, Enssle KH. Modulation of the immunoglobulin dysretulation in GvH- and SLE-like diseases by the murine IL-4 receptor (IL-4-R). Inflamm Res 1995;44:S1946.
54. 1 mice. J Exp Med 1994;179:305-10.
55. Kalechman Y, Gafter U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B, Delay in the onset of systemic lupus crythcmatosus following treatment with the immunomodulator AS101: Association with IL-10 inhibition and increase in TNF-alpha levels. J Immunol 1997;159: 2658-67.
56. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44.
57. Georgescu L, Vakkalanka RK, Elkon KB, Crow MI. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997;100:2622-33.
58. Jacob CO, McDevitt HO. Tumor necrosis factor alpha in murine autoimmune "lupus" nephritis. Nature (Lond) 1988;331:356-8.
59. Richter G, Qin ZM, Diamantstein T, Blankenstein T. Analysis of restriction fragment length polymorphism in lymphokine genes of normal and autoimmune mice. J Exp Med 1989;170:1439-43.
60. Jacob CO, Tashman NB. Disruption in the AU motif of the mouse TNF-alpha 3' UTR correlates with reduced TNF production by macrophages in vitro. Nucleic Acids Res 1993;21:2761-6.
61. Jacob CO, Lee SK, Strassman G. Mutational analysis of TNFα gene reveals a regulatory role for the 3'-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996;156:3043-50.
62. Fujimura T, Hirose S, Jiang Y, et al. Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int Immunol 1998;10:1467-72.
63. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989;143:3470-5.
64. Nakamura T, Ebihara I, Fukui M, et al. Renal expression of mRNAs for endothdin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem 1993; 16:233-43.
65. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988;141: 3050-4.
66. Moore KJ, Yeh K, Naito T, Kelley VR. TNF-α enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J Immunol 1996;157: 427-32.
67. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995;47:122-30.
68. Alleva DG, Kaser SB, Beller DI. Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL-+/+ and NZB/W F1 lupus-prone mice. J Immunol 1997;59:5610-19.
69. Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha IAG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993;2: 359-65.
70. Aderka D, Wysenbeck A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
71. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and it soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
72. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995;26:558-64.
73. Jacob CO, Hwang F, Lewis GD, Stall AM. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: Implications for genetic predisposition and immune regulation. Cytokine 1991;3:551-61.
74. 1 mice. Clin Immunol Immunopathol 1989;52:421-34.
75. Deguchi Y, Kishimoto S. Tumour necrosis factor/cachetin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol 1991;85:392-5.
76. Taylor GA, Carballo E, Lee DM, et al. A pathogenetic role for TNFα in the syndrome of cachexia, arthritis and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996;4:445-54.
77. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998;281:1001-5.
78. Su X, Zhou T, Yang P, Edwards CK 3rd, Mountz JD. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum 1998;41:139-49.
79. Edwards CK III, Zhou T, Zhang J, et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α. J Immunol 1996;157: 1758-72.
80. Watanabe Y, Jacob CO. Regulation of MHC class II antigen expression. Opposing effects of tumor necrosis factor-alpha on IFN-gamma-induced HLA-DR and Ia expression depends on the maturation and differentiation stage of the cell. J Immunol 1991;146:899-905.
81. Yang XD, Tisch R, Singer SM, et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994;180:995-1004.
82. Dorner T, Hucko M, Mayet WJ, Trefzer U, Burmester GR, Hiepe F. Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF alpha. Ann Rheum Dis 1995;54:904-9.
83. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor alpha on immune function. J Immunol 1996;144:1753-8.
84. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-84.
85. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998;10:669-76.
86. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397-440.
87. Hunger RE, Carnaud C, Garcia I, Vassalli, P, Mueller C. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 1997;27:255-61.
88. Hunger RE, Muller S, Laissue JA, et al. Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55. J Clin Invest 1996;98:954-61.
89. Hill CM, Lunee J. The TNF-ligand and receptor superfamilies: Controllers of immunity and the Trojan horses of autoimmune disease? Mol Aspects Med 1996;17: 455-509.
90. Jacob CO. Tumor necrosis factor in autoimmunity: Pretty girl or old witch? Immunol Today 1992;13:122-5.
91. Mao C, Singh AK. IL-1 beta gene expression in B cells derived from the rnurine MRL/lpr model of lupus. Autoimmunity 1996;24:71-9.
92. Lebedeva TV, Singh AK. Increased responsiveness of B cells in the murine MRL/lpr model of lupus nephritis to interleukin-1 beta. J Am Soc Nephrol 1995;5:1530-4.
93. 1 hybrid mice and MRL autoimmune mice. Agents Actions 1993;39: C117-20.
94. Kiberd BA, Stadnyk AW. Established murinc lupus nephritis does not respond to exogenous interleukin-I receptor antagonist: A role for the endogenous molecule? Immunopharmacology 1995;30:131-7.
95. Singh AK, Lebedeva TV. Interleukin-1 contributes to high level IgG production in the murine MRL/lpr lupus model. Immunol Invest 1994;23:281-92.
96. Singh AK, Mao C, Lebedeva TV. In vitro role of IL-1 in heightened IgG, anti-DNA, and nephritogenic idiotype production by B cells derived from the murine MRL/lpr lupus model. Clin Immunol Immunopathol 1994;72:410-15.
97. Lowrance JH, O'Sullivan FX, Caver TE, Wacgell W, Gresham HD. Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med 1994; 180:1693-703.
98. Caver TE, O'Sullivan FX, Gold LI, Gresham HD. Intracellular demonstration of active TGFβ1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFβ1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J Clin Invest 1996;98:2496-506.